Nabriva Therapeutics (NBRV) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by StockNews.comNovember 21 at 3:09 AM | americanbankingnews.comStockNews.com Begins Coverage on Nabriva Therapeutics (NASDAQ:NBRV)November 13, 2024 | americanbankingnews.comNabriva Therapeutics plc (NBRVF)October 19, 2024 | finance.yahoo.comNabriva Therapeutics PLC NBRVFApril 13, 2024 | morningstar.comArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesJuly 11, 2023 | finanznachrichten.deNBRV - Nabriva Therapeutics plcMay 26, 2023 | finance.yahoo.comTrading was temporarily halted for "NBRV" at 09:03 AM with a stated reason of "LULD pause."March 27, 2023 | marketbeat.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 28, 2023 | marketwatch.comNBRV Nabriva Therapeutics plcFebruary 25, 2023 | seekingalpha.comNabriva Therapeutics Provides Corporate UpdateJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | marketwatch.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | markets.businessinsider.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | bizjournals.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | seekingalpha.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | finance.yahoo.comMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | finance.yahoo.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | technews.tmcnet.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022November 7, 2022 | finance.yahoo.comNabriva Therapeutics plc (NASDAQ:NBRV) Sees Significant Drop in Short InterestNabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 532,200 shares, a drop of 13.0% from the August 15th total of 611,800 shares. Based on an average trading volume of 804,800 shares, the short-interest ratio is presently 0.7 days.September 18, 2022 | marketbeat.comNabriva Therapeutics (NASDAQ:NBRV) Reaches New 12-Month High on Analyst UpgradeNabriva Therapeutics (NASDAQ:NBRV) Reaches New 12-Month High on Analyst UpgradeSeptember 16, 2022 | marketbeat.comNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitSeptember 15, 2022 | finance.yahoo.comAll You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to BuySeptember 14, 2022 | finance.yahoo.comNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | finance.yahoo.comNabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Up 24.1% in JulyNabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 709,000 shares, an increase of 24.1% from the July 15th total of 571,100 shares. Based on an average trading volume of 807,800 shares, the days-to-cover ratio is currently 0.9 days.August 15, 2022 | marketbeat.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic FibrosisAugust 12, 2022 | marketwatch.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisAugust 11, 2022 | finance.yahoo.comNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | seekingalpha.comNabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateAugust 3, 2022 | finance.yahoo.comNabriva Therapeutics (NBRV) to Release Quarterly Earnings on WednesdayNabriva Therapeutics (NASDAQ:NBRV) will be releasing earnings after the market closes on Wednesday, August 3, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=465996)July 27, 2022 | marketbeat.comNabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022July 20, 2022 | finance.yahoo.comNabriva Inks Exclusive Distribution Agreement With Er-KimJuly 18, 2022 | markets.businessinsider.comNabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsJuly 18, 2022 | finance.yahoo.comNabriva Therapeutics plc (NASDAQ:NBRV) Sees Large Decline in Short InterestNabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 535,500 shares, a decrease of 21.0% from the April 30th total of 677,700 shares. Based on an average trading volume of 475,200 shares, the short-interest ratio is currently 1.1 days.May 31, 2022 | marketbeat.com$9.47 Million in Sales Expected for Nabriva Therapeutics plc (NASDAQ:NBRV) This QuarterBrokerages predict that Nabriva Therapeutics plc (NASDAQ:NBRV - Get Rating) will report $9.47 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Nabriva Therapeutics' earnings. The highest sales estimate is $10.40 million and the lowest is $8.May 25, 2022 | marketbeat.comNabriva Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceMay 13, 2022 | finance.yahoo.comNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call TranscriptMay 8, 2022 | seekingalpha.comNabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateMay 5, 2022 | finance.yahoo.comNabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in USMay 5, 2022 | seekingalpha.comNabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026May 5, 2022 | finance.yahoo.comA Preview Of Nabriva Therapeutics's EarningsMay 4, 2022 | benzinga.comNabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022May 2, 2022 | finance.yahoo.comNabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisApril 11, 2022 | finance.yahoo.comNorthland Securities slashes Nabriva Therapeutics' price targetMarch 30, 2022 | seekingalpha.comNabriva Therapeutics (NASDAQ:NBRV) Price Target Cut to $2.00Northland Securities dropped their price objective on Nabriva Therapeutics from $4.00 to $2.00 in a research note on Wednesday.March 30, 2022 | marketbeat.comNabriva Therapeutics plc 2021 Q4 - Results - Earnings Call PresentationMarch 29, 2022 | seekingalpha.comNabriva Therapeutics Earnings, Revenue Miss in Q1March 29, 2022 | investing.com Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address “Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. Learn these 4 simple steps and protect your savings before it’s too late. NBRV Media Mentions By Week NBRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBRV News Sentiment▼0.000.49▲Average Medical News Sentiment NBRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBRV Articles This Week▼10▲NBRV Articles Average Week Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCYX News NBTX News DMAC News ACTU News VSTM News SCPH News INZY News NKTX News GALT News GLSI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBRV) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBRV Stock Alerts